The AI drug discovery sector is evolving, with significant investments from global pharmaceutical companies. In China, two firms, XtalPi and InSilico Medicine, are adopting distinct business models: XtalPi focuses on selling AI-powered research services, while InSilico develops innovative biotech pipelines. XtalPi recently reported a remarkable revenue increase of over 200% and achieved profitability, becoming the first AI for Science company to earn a profit on Hong Kong’s H-share market. In contrast, InSilico posted a revenue of $56.2 million with a notable net loss, further fueling the debate on how AI should be commercialized in the biotech field.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.chinadaily.com.cn/a/202604/17/WS69e19236a310d6866eb43f9f.html
